Jesus Lopez-Marti

Jesus Lopez-Marti

Auto-generated profile, based on publicly available information

Jesus Lopez-Marti

Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
TPTea Pemovska
Tea Pemovska
MKMika Kontro
Mika Kontro
BYBhagwan Yadav
Bhagwan Yadav
HEHenrik Edgren
Henrik Edgren
SESamuli Eldfors
Samuli Eldfors
KWKrister Wennerberg
Krister Wennerberg
We present an individualized systems medicine (ISM) approach to optimize cancer drug therapies one patient at a time. ISM is based on (i) molecular profiling and ex vivo drug sensitivity and resistance testing (DSRT) of patients' cancer cells to 187 oncology drugs, (ii) clinical implementation of therapies predicted to be effective, and (iii) studying consecutive samples from the treated patients to understand the basis of resistance. Here, application of ISM to 28 samples from patients with acute myeloid leukemia (AML) uncovered five major taxonomic drug-response subtypes based on DSRT profiles, some with distinct genomic features (e.g., MLL gene fusions in subgroup IV and FLT3-ITD mutations in subgroup V). Therapy based on DSRT resulted in several clinical responses. After progression under DSRT-guided therapies, AML cells displayed significant clonal evolution and novel genomic changes potentially explaining resistance, whereas ex vivo DSRT data showed resistance to the clinically applied drugs and new vulnerabilities to previously ineffective drugs. Significance: Here, we demonstrate an ISM strategy to optimize safe and effective personalized cancer therapies for individual patients as well as to understand and predict disease evolution and the next line of therapy. This approach could facilitate systematic drug repositioning of approved targeted drugs as well as help to prioritize and de-risk emerging drugs for clinical testing. Cancer Discov; 3(12); 1416–29. ©2013 AACR. See related commentary by Hourigan and Karp, p. 1336 This article is highlighted in the In This Issue feature, p. 1317

27 February 2014 in Leukemia
Verified
Journal Article
Open access
PDF file
MKM Kontro
M Kontro
HKHeikki Kuusanmäki
Heikki Kuusanmäki
SESamuli Eldfors
Samuli Eldfors
TBT Burmeister
T Burmeister
EAE I Andersson
E I Andersson
Caroline HeckmanCaroline Heckman
Caroline Heckman

1 March 2001 in Obesity Research
Verified
Journal Article
Open access
PDF file
MGMaria Mar Del Grasa
Maria Mar Del Grasa
CCCristina Cabot
Cristina Cabot
Montserrat EsteveMontserrat Esteve
Montserrat Esteve
PYPilar Yubero
Pilar Yubero
RMRosa Maria Masanés
Rosa Maria Masanés
MAMarià Alemany
Marià Alemany
Objective: To establish whether single daily oral doses of oleoyl‐estrone result in dose‐dependent slimming effects on normal weight rats, and to determine the changes in energy parameters induced by this treatment. Research Methods and Procedures: The effects of a daily oral gavage of oleoyl‐estrone (0, 0.2, 0.5, 1, 2, 5, 10, and 20 μmol/kg per day) in 0.2 ml of sunflower oil given over a 10‐day period were studied in groups, each of which contained six adult female Wistar rats initially weighing 190 to 230 g. A group of intact control rats receiving no gavage was included for comparison. Body weight and food intake were measured daily. Rats were killed on day 10 of treatment, and body composition (protein nitrogen, lipids, and water), liver lipids, and plasma parameters (glucose, triacylglycerols, total cholesterol, free fatty acids, 3‐hydroxybutyrate, urea, aspartate, alanine transaminases, insulin, leptin, and free and acyl‐estrone) were measured. Results: The administration of oleoyl‐estrone resulted in a dose‐dependent loss of body fat, because of a partly maintained energy expenditure combined with decreased food intake. The differences in the energy budget were met by internal fat pools. The changes recorded did not affect the levels of the main plasma energy homeostasis indicators: unaltered glucose, triacylglycerols, free fatty acids, 3hydroxybutyrate, and urea. Protein was accrued even under conditions of severe lipid store drainage. There were no changes in transaminases. No lipid accumulation was recorded in the liver. Plasma insulin and leptin levels decreased with increased oleoyl‐estrone doses, whereas the levels of free and esterified estrone increased with treatment, although not in proportion to the dose received. Discussion: Oral treatment with oleoyl‐estrone resulted in the specific dose‐related loss of fat reserves with little change to other metabolic parameters. These results agree with the postulated role of oleoyl‐estrone as a ponderostat signal.

1 November 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FCFabio Casagrande
Fabio Casagrande
MRMerce Ratera
Merce Ratera
ASAndreas D. Schenk
Andreas D. Schenk
MCMohamed Chami
Mohamed Chami
EVEva Valencia
Eva Valencia
DFDimitrios Fotiadis
Dimitrios Fotiadis
The l-arginine/agmatine antiporter AdiC is a key component of the arginine-dependent extreme acid resistance system of Escherichia coli. Phylogenetic analysis indicated that AdiC belongs to the amino acid/polyamine/organocation (APC) transporter superfamily having sequence identities of 15–17% to eukaryotic and human APC transporters. For functional and structural characterization, we cloned, overexpressed, and purified wild-type AdiC and the point mutant AdiC-W293L, which is unable to bind and consequently transport l-arginine. Purified detergent-solubilized AdiC particles were dimeric. Reconstitution experiments yielded two-dimensional crystals of AdiC-W293L diffracting beyond 6 Å resolution from which we determined the projection structure at 6.5 Å resolution. The projection map showed 10–12 density peaks per monomer and suggested mainly tilted helices with the exception of one distinct perpendicular membrane spanning α-helix. Comparison of AdiC-W293L with the projection map of the oxalate/formate antiporter from Oxalobacter formigenes, a member from the major facilitator superfamily, indicated different structures. Thus, two-dimensional crystals of AdiC-W293L yielded the first detailed view of a transport protein from the APC superfamily at sub-nanometer resolution.

1 March 2003 in Transplantation
Verified
Journal Article
Closed access
ASAnna Sola
Anna Sola
LPL. Palacios
L. Palacios
JLJ. López-Martí
J. López-Martí
AIAntoni Ivorra
Antoni Ivorra
NNN. Noguera
N. Noguera
GHGeorgina Hotter
Georgina Hotter
Background. Microelectrode technology is a promising tool for monitoring kidney ischemia and the changes induced by its therapeutic management. Ischemic preconditioning, that is, brief ischemic periods before sustained ischemia, has been shown to protect several organs, including the kidney, from ischemia-reperfusion injury. We tested whether the effect of preconditioning could be appraised by real-time measurement of parameters representative of tissue hypoxia. Methods. In a sample of pentobarbital-anesthetized and mechanically ventilated rats, we studied the effect of renal ischemic preconditioning (10-min ischemia and 10-min reflow interval) on subsequent ischemia-reperfusion (45 min and 60 min). Renal tissue electrical impedance, extracellular pH, and potassium concentration [K+] were measured continuously by implanted microelectrodes. Results. Ischemia induced an early, rapid rise in extracellular potassium and impedance module, followed by a phase of slower increase, whereas pH decreased rapidly, reaching a plateau. Preconditioning treatment did not cause significant changes in interstitial pH and [K+] but increased ischemic tissue impedance. During reperfusion, the three variables recovered progressively; however, after a decline, electrical impedance showed a clear postischemic increase. This rise was suppressed by preconditioning. Conclusions. Real-time measurement of any of the three parameters showed capability for early detection of ischemia. In contrast with findings in myocardial tissue, preconditioning in the kidney did not increase potassium cell loss during ischemia or improve ischemic acidosis or tissue impedance. Electrical impedance increased for a second time during reperfusion, indicating the presence of a postischemic cellular edema; concealing this episode was the most noticeable effect of the preconditioning treatment.

1 June 2001 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
MGMar Grasa
Mar Grasa
Montserrat EsteveMontserrat Esteve
Montserrat Esteve
RMR. M. Masanés
R. M. Masanés
PYP. Yubero
P. Yubero
M Teresa BlayM Teresa Blay
M Teresa Blay
MAMarià Alemany
Marià Alemany